www.m4.dem4 g P4Horst DomdeyBioM
www.m4.deClusterManagementfor MunichHospitalsin MunichBiotechand Pharmain MunichSciencein MunichPersonalized Medicine in M...
www.m4.deIn June 2012 Corimmunwas acquired by Jansen-CilagCOR-1 is a cyclic peptidewhich neutralizesstimulatory autoimmune...
www.m4.dem4 Scouting & Incubation• m4 ScoutingIdentification of (bio)pharmaceutical researchprojects with a high innovatio...
www.m4.dePredictiveBiomarkers- DNA/RNA-omics- ProteomicsP4 Medicine – Healthcare of the FuturePersonalizedStratification o...
www.m4.de4 Challenges1. Health Economics2. Alternative individualized treatments3. Biomarkers4. IT
Upcoming SlideShare
Loading in …5
×

EuroBioForum 2013 - Day 1 | Horst Domdey

439 views

Published on

EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013

=======================================

# KEYNOTE PRESENTATION #

m4 -> P4

Dr Horst Domdey
Managing Director at BioM
(co-host of EuroBioForum 2nd Annual Conference 2013)

=======================================

http://www.eurobioforum.eu

Published in: Health & Medicine, Business
  • Be the first to comment

  • Be the first to like this

EuroBioForum 2013 - Day 1 | Horst Domdey

  1. 1. www.m4.dem4 g P4Horst DomdeyBioM
  2. 2. www.m4.deClusterManagementfor MunichHospitalsin MunichBiotechand Pharmain MunichSciencein MunichPersonalized Medicine in Munich€ 100 MProgramonPersonalizedMedicine
  3. 3. www.m4.deIn June 2012 Corimmunwas acquired by Jansen-CilagCOR-1 is a cyclic peptidewhich neutralizesstimulatory autoimmuneantibodies directed againstthe beta-adrenergic receptormimicking the effect ofnatural ligands likeadrenaline and thus leadingto a chronic over-stimulationof the receptor.Consequently this leads tohypertrophy and reducedfunction of the heart.• Ex vivo, COR-1 showed goodefficacy to neutralize anti ß1receptor autoantibodies.• In animal models, COR-1prevented the generation of heartfailure and also reversed existingheart failure.• In a placebo-controlled phaseI clinical trial COR-1 was shownto be well tolerated.• COR-1 is now being investigatedin a phase II clinical trial; it isadministered to a subgroup ofheart failure patients who havebeen stratified by a specificdiagnostic test.COR-1 – an m4 Lighthouse Project
  4. 4. www.m4.dem4 Scouting & Incubation• m4 ScoutingIdentification of (bio)pharmaceutical researchprojects with a high innovationspotentia• m4 AwardRegional pre-seed program for innovativeresearch projects in the field of biomarkersand drug development• m4 Mentor CircleProfessional mentoring by retired experts fromacademia and industry• m4 IncubationAssisted incubation of the m4 Award projects
  5. 5. www.m4.dePredictiveBiomarkers- DNA/RNA-omics- ProteomicsP4 Medicine – Healthcare of the FuturePersonalizedStratification of Patients- Herceptin- Erbitux- . . .PreventiveLife Style and Treatment- Phenylketonuria- Diabetes- CancerParticipatoryInformed Decisionsby informed Patients- 1000$ Genome
  6. 6. www.m4.de4 Challenges1. Health Economics2. Alternative individualized treatments3. Biomarkers4. IT

×